ArticleCancer cell international2026
Urinary miR-191-5p levels are significantly reduced after radical prostatectomy in patients with prostate cancer.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroRNAs (miRNA) detection in urine samples may be a scarce invasive approach for diagnosis and monitoring prostate cancer (PCa). The role of miR-191-5p in prostate oncogenesis, as well as its function as a potential diagnostic and prognostic biomarker has been described in many cancers. However, its role as a diagnostic non-invasive indicator in PCa is still under investigated.
methodsWe performed an extracellular vesicle (EV)-based miRNA-sequencing of urine samples (n = 12/group) collected from PCa patients before (T0) and three months after (T1) radical prostatectomy, and healthy individuals. An independent cohort of PCa paired urine samples (n = 25/group) and controls (n = 22) was used to validate our sequencing data by RT-qPCR. Furthermore, we conducted comprehensive in silico analyses on urine and tissue samples extracted from Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases, respectively. Receiver operator curves analysis was employed to assess the diagnostic value of miR-191-5p. To explore the role(s) of miR-191-5p in prostate carcinogenesis, we predicted miR-191-5p potential targets using four miRNA/target-gene pair databases (i.e., miRDB, miRTarBase, TarBase, and TargetScan). Finally, we corroborated the potential correlation between miR-191-5p and its targets by in silico investigation using TCGA dataset.
resultsDifferential expression analysis revealed a significant upregulation of miR-191-5p in PCa patients compared to healthy individuals. Remarkably, urinary miR-191-5p expression levels significantly decreased after surgery in both our discovery and validation cohorts of urine samples by miRNA-seq and RT-qPCR, respectively. Bioinformatics analyses further confirmed high levels of miR-191-5p in urine and tissue samples from PCa patients compared to controls, particularly in patients with high Gleason score. Moreover, miR-191-5p showed a strong diagnostic value in urine and tissue samples. Finally, target prediction analysis identified the genes Satb1 and Ctdsp2 as potential targets of miR-191-5p. This was supported by a significant inverse correlation between the expression of miR-191-5p and these genes in TCGA PCa tissues. Moreover, both Satb1 and Ctdsp2 were downregulated in PCa tissues, and especially in high Gleason score tumors compared to normal and low Gleason score samples.
conclusionsMiR-191-5p is highly expressed in urine and tissue samples from patients with prostate cancer. Our findings, although preliminary, support miR-191-5p as a promising minimally invasive biomarker for diagnosis of PCa patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.